ClinicalTrials.gg

Program

Bilpatide

Also written as “RAY1225” and “14C-RAY1225”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by Guangdong Zhongsheng Pharmaceutical.

Furthest: phase 3, since Mar 18, 202512 company-led studies, 8 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangdong Zhongsheng Pharmaceutical128 open or runningphase 3since Mar 18, 2025Apr 11, 2023Dec 1, 2026phase 3 · NCT07139535

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 11, 2023First study: phase 1 study in ObesityFirst studyNCT05835752 · 68 enrolled · China
  2. Feb 3, 20242 phase 2 studiesNCT06254274, NCT06254261
  3. Aug 27, 20242 phase 1 studiesNCT06577428, NCT06577415
  4. Sep 23, 2024Phase 1 study in Renal InsufficiencyNCT06613763 · 32 enrolled · China
  5. Mar 18, 2025Phase 3 study in ObesityNCT06893016 · 640 planned · China
  6. Aug 11, 20252 phase 3 studies in T2DMNCT07139548, NCT07139535
  7. Jan 14, 2026Phase 1 study in ObesityNCT07362030 · 32 enrolled · China
  8. Feb 27, 2026Phase 1 study in Basic ScienceNCT07460284 · 8 planned · China
  9. Sep 14, 2026Phase 1 study in Basic ScienceNCT07827027 · 68 planned

Ahead

  1. Nov 5, 2026Primary completion: phase 1 study in Basic ScienceNCT07827027
  2. Dec 1, 2026Primary completion: phase 3 study in T2DMNCT07139548
  3. Dec 1, 2026Primary completion: phase 3 study in T2DMNCT07139535

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07827027Basic Science1Not yet recruitingNov 5, 202668
NCT07460284Basic Science · China1Not yet recruitingOct 14, 20268
NCT07362030Obesity · China1Active, not recruitingDec 27, 202532
NCT07139548T2DM · China3Not yet recruitingDec 1, 2026600
NCT07139535T2DM · China3Not yet recruitingDec 1, 2026350
NCT06893016Obesity · China3RecruitingJun 15, 2026640
NCT06613763Renal Insufficiency · China1CompletedJan 10, 202532
NCT06577428Healthy · China1CompletedSep 29, 202448
NCT06577415Hepatic Impairment · China1RecruitingOct 31, 202524
NCT06254274Diabetes Mellitus, Type 2 · China2CompletedJul 20, 2025210
NCT06254261Obesity · China2RecruitingDec 20, 2025270
NCT05835752Obesity · China1CompletedMar 1, 202468

How it is read

Names in the registry

  • “RAY1225”, 13 entries
  • “14C-RAY1225”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.